Clinical trials
Primary Sclerosing Cholangitis clinical trials
Below are recruiting primary sclerosing cholangitis clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04753996Recruiting
Testing bile-based “mini-liver” samples in PSC and non-PSC groups
This study collects bile and uses it to grow small lab models (organoids) from people with primary sclerosing cholangitis (PSC) and from people without PSC. Researchers want to better understand how PSC changes bile cells, which could improve future diagnosis or treatments.
Rochester, MinnesotaAges 18–85 - NCT05750498Recruiting
Study to improve outcomes in autoimmune liver disease
This trial tests approaches to improve health outcomes for people with autoimmune liver diseases. It includes specific autoimmune conditions affecting the liver and bile ducts, and it may help your care team learn what works best for these illnesses.
Palo Alto, CaliforniaAges Any age - NCT06197308RecruitingEarly Phase 1
Testing a mouth bacteria treatment for PSC
This study tests whether a treatment made from mouth bacteria can help people with primary sclerosing cholangitis (PSC). It aims to see if it's safe and improves health.
Minneapolis, MinnesotaAges 18–76 - NCT06455280RecruitingPhase 1
A study of Siplizumab for autoimmune liver disease patients awaiting transplant
This trial tests a drug called Siplizumab in people with autoimmune hepatitis or primary sclerosing cholangitis who are on the liver transplant waitlist. It aims to see if the drug can help manage their condition before and after transplant.
New York, New YorkAges 18 years+ - NCT06699121RecruitingPhase 2
Testing LB-P8 for people with primary sclerosing cholangitis
This trial tests a new treatment called LB-P8 for people with primary sclerosing cholangitis (PSC), a liver disease. It aims to see if LB-P8 is safe and can help slow the disease down. You may join if you meet certain health requirements.
Sacramento, CaliforniaAges 18–75 - NCT03178630Recruiting
MRI scans to track outcomes in children with autoimmune liver disease
This study uses MRI scans to find “biomarkers,” or imaging clues, that may help predict how autoimmune liver conditions will progress in children and young adults. If you qualify, you may get MRI imaging to see whether it relates to future health outcomes.
Cincinnati, OhioAges 6–23 - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT07205874Recruiting
Finding PBC early in people with positive AMA
This study looks for early signs of Primary Biliary Cholangitis in people who have a positive AMA blood test but normal liver enzyme levels. It aims to find the disease before it causes symptoms.
MadridAges 18–80 - NCT06864195Recruiting
Breath test for liver cancer detection
This study tests a simple breath test to detect liver cancer and monitor liver health. It is looking for patients with liver cancer, liver cirrhosis, primary sclerosing cholangitis, or people with normal livers to see if the breath test can help tell the difference.
LondonAges 18 years+ - NCT07282353RecruitingPhase 3
Study of CS0159 for primary biliary cholangitis with poor UDCA response
This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.
Hefei, AnhuiAges 18–75 - NCT07149675Recruiting
Long-term study for primary biliary cholangitis patients
This study tracks patients with primary biliary cholangitis (PBC) over time to understand long-term outcomes. It aims to gather information that could improve care and management for people with PBC.
Beijing, Select A State Or ProvinceAges Any age - NCT07296458RecruitingPhase 3
Fenofibrate for first-line treatment of primary biliary cholangitis
This study tests whether fenofibrate, a medicine that lowers fats in the blood, can help people with primary biliary cholangitis (a chronic liver disease) who haven't had treatment before. It aims to see if it is safe and effective as a first treatment option.
Xi'an, ShaanxiAges 18–75
Hear when a new Primary Sclerosing Cholangitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary sclerosing cholangitis?
- Yes. Clin2 currently lists 36 recruiting primary sclerosing cholangitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary sclerosing cholangitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary sclerosing cholangitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.